Targeting colorectal cancer stem cells with inducible caspase-9
Colorectal cancer stem cells (CSCs) drive tumor growth and are suggested to initiate distant metastases. Moreover, colon CSCs are reportedly more resistant to conventional chemotherapy, which is in part due to upregulation of anti-apoptotic Bcl-2 family members. To determine whether we could circumvent this apoptotic blockade, we made use of an inducible active caspase-9 (iCasp9) construct to target CSCs. Dimerization of iCasp9 with AP20187 in HCT116 colorectal cancer cells resulted in massive and rapid induction of apoptosis. In contrast to fluorouracil (5-FU)-induced apoptosis, iCasp9-induced apoptosis was independent of the mitochondrial pathway as evidenced by Bax/Bak double deficient HCT116 cells. Dimerizer treatment of colon CSCs transduced with iCasp9 (CSC-iCasp9) also rapidly induced high levels of apoptosis, while these cells were unresponsive to 5-FU in vitro. More importantly, injection of the dimerizer into mice that developed a colon CSC-iCasp9-induced tumor resulted in a strong decrease in tumor size, an increase in tumor cell apoptosis and a clear loss of CD133+ CSCs. Taken together, our data indicate that dimerization of iCasp9 circumvents the apoptosis block in CSCs, which results in effective tumor regression in vivo.
KeywordsCancer stem cellInducible caspase-9TherapyResistence
Cancer stem cells (CSCs), also called tumor-initiating cells, were first identified in haematological malignancies, but more recently these cells were also described in solid tumors, like colorectal cancer (CRC) [1–4]. CSCs are a subpopulation of cells within the tumor that contain self-renewal capacity and the ability to differentiate. Therefore, they are thought to be the driving force behind tumor growth and metastasis. In vitro experiments have shown that colon CSCs are more resistant to treatment with fluorouracil (5-FU) and oxaliplatin compared to their more differentiated progeny [3, 5] and therefore, CSCs are thought to be responsible for tumor recurrence after treatment.
Chemoresistance of tumor cells can be caused by alterations in the expression of apoptotic and anti-apoptotic genes . Apoptosis can be triggered by the extrinsic pathway, initiated by ligation of death receptors on the cell surface leading to caspase-8 activation, or by the intrinsic pathway, which leads to cytochrome c release from the mitochondria . Release of cytochrome c is regulated by Bax and Bak-dependent mitochondrial permeabilization and is counteracted by the anti-apoptotic Bcl-2 family members. Cytochrome c release is a crucial step in the assembly of the apoptosome, which in effect results in caspase-9 activation through induced proximity and subsequently cumulates in proteolytic cleavage and thereby activation of the downstream executioner caspases-3 and -7.
Evasion of apoptosis is one of the hallmarks of cancer . Resistance to chemotherapy-induced apoptosis in CRC tumors is in part due to upregulation of anti-apoptotic molecules and downregulation of pro-apoptotic molecules. For instance, the expression level of anti-apoptotic molecule Bcl-2 has been reported to increase during the early stages of colorectal tumorigenesis . On the other hand, pro-apoptotic molecules like Bax and Bak  are decreased in CRC tumors. Low levels of pro-apoptotic molecule Bax have been shown to correlate to 5-FU resistance . In addition, more than 50% of colon tumors with defects in mismatch repair harbor mutations in Bax, thereby compromising its function in apoptosis . CRCs therefore appear to escape from therapy-induced apoptosis by changes in the expression of apoptosis-regulatory genes.
Unlike executioner caspases, such as caspase-3, that are activated by cleavage, caspase-9 undergoes a conformational change when two caspase-9 molecules are brought into close proximity. This opens up the catalytic site and unleashes the proteolytic activity. Based on the same principle an inducible system has been developed where the catalytic domain of caspase-9 is fused to a modified FK506-binding domain (FKBP) that can be homodimerized by addition of an optimized chemical inducer of dimerization (CID) AP20187 . The dimerizer is membrane-permeable and binds at subnanomolar concentrations to the modified FKBP, while the affinity for the endogenous FKBP is 1,000-fold lower. Therefore addition of the dimerizer brings two inducible caspase-9 (iCasp9) molecules into close proximity and thereby rapidly activates downstream executioner caspases in a cytochrome c-independent fashion. In contrast to other inducible suicide systems, such as the HSV-1-derived thymidine kinase (HSV-TK)/ganciclovir (GCV) method, the mode of action of iCasp9 does not rely on proliferation, which makes it ideal to target CSCs, as these have been shown under certain conditions to be quiescent or slow cycling [13–16]. In addition, HSV-TK has been shown to induce a bystander effect, since the prodrug GCV, when converted to its active form by HSV-TK, can spread to other cells and also exert its inhibitory function in cells that do not express HSV-TK. In contrast, iCasp9-induced apoptosis is cell autonomous and a more reliable method to selectively target individual cells without collateral damage. Lastly, since caspase-9 is downstream of the mitochondria the sensitivity of cells to its activation should be independent of the Bcl-2 family of proteins.
The iCasp9 construct has been tested in an in vitro and in vivo xenograft model for prostate cancer , but the cytotoxic effect on CSCs was not taken into consideration in this study. Since CSCs are known to be resistant to conventional therapy, we decided to study the effect of dimerization of iCasp9 in these cells. We show here that CRC cells that have lost pro-apoptotic proteins are still responsive to the dimerization of iCasp9. More importantly, colon CSCs are very effectively killed by dimerization of iCasp9 both in vitro and in vivo.
Materials and methods
Cell lines, culture, vectors, transduction, selection and dimerizer treatment
HCT116 lines were derived from Dr. G. C. Chinnadurai (St. Louis University School of Medicine, USA) and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) containing 8% fetal calf serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. The CSC line, obtained from a primary carcinoma under standard medical ethical procedures of the Academic Medical Center was derived and cultured as described previously . PMX-iCasp9-IRES-GFP and pMX-IRES-YFP virus were produced in Phoenix cells and virus was harvested after 48 h. Transduction was performed overnight with addition of 10 μg/ml polybrene. Transduced cells were selected by sorting for GFP/YFP expression. Treatment was performed with 10 nM dimerizer AP20187 obtained from ARIAD Pharmaceuticals (Cambridge, MA, USA) or 500 μg/ml 5-FU.
FACS analysis, active caspase-3 assay, Annexin-V staining and limiting dilution assay (LDA)
Cell death was analyzed by FACS using PI-positivity (200 ng/ml) and apoptosis was analyzed by DNA fragmentation using a Nicoletti assay. To this end cells were incubated overnight in Nicoletti buffer (0.1% Na-citrate, 0.1% Triton-X-100 and 50 μg/ml PI in H20) and analyzed the next day. Activity of caspase-3 was analyzed by CaspGLOW Red Active Caspase-3 Staining Kit (K193-100, Biovision) according to manufacturer’s protocol. Cells were stained for CD133 (AC133, Miltenyi) to identify the CSC fraction. Early apoptosis was analyzed by Annexin-V staining (550474, BD Biosciences). Xenografts were dissociated with 1.5 mg/ml of collagenase II (C6885, Sigma) and 20 μg/ml of hyaluronidase (H4272, Sigma) at 37°C for 30 min. Cells were then stained in PBA (PBS with 1% BSA and 0.02% sodium azide) for PE-anti-Epcam (EBA-1, BD Biosciences) and APC-anti-CD133 (AC133, Miltenyi). All analyses were performed on the FACS Canto (BD Biosciences), while further analyses were performed in FlowJo (BD Biosciences). For LDA, cells were deposited by FACSAria in a 96-well plate as 1, 2, 4, 8, 10, 12, 16, 20 and 24 cells per well in at least 8 wells per condition. After two weeks, the presence of spheroids in each well was scored.
Cell lyses, western blotting and antibodies
Cells were lysed in Triton-X-100 lysis buffer (20 mM Tris HCl, pH 7.4, 137 mM NaCl, 10% Glycerin, 1% Triton-X-100, 2 mM EDTA, 2 μg/ml Aprotinin, 10 μg/ml Leupeptin). Protein amounts were measured by BCA protein assay (Thermo Scientific Pierce) according to the manufacturer’s protocol. Per lane, 20 μg protein was loaded on 12% acryl amide gels and blotted onto nitrocellulose membrane. Unspecific binding was blocked in blocking buffer (LICOR). Membranes were incubated overnight at 4°C with rabbit-anti-cleaved caspase 3 (9661, Cell Signaling), rabbit-anti-PARP (9542, Cell Signaling) or mouse-anti-beta I tubulin (T7816, Sigma). After washing in PBS-0.2% Tween, membranes were incubated for 1 h at RT with IRDye 680-anti-rabbit IgG (LICOR) or IRDye 800 anti-mouse IgG (LICOR). Membranes were developed with the Odyssey (LICOR).
In vivo tumor growth
All animal experimentation was approved by the Dier Experimentele Commissie (DEC) of the institute. C002-iCasp9-IRES-GFP cells were injected subcutaneously in male athymic Balb/cOlaHsd-Foxn1nu mice (Harlan). In the first experiment, when tumors reached an average size of 200 mm3, the mice were treated with either one (day 0) or two intraperitonial injections (day 0, 2) of 1 mg/kg AP20187 dissolved 4% ethanol, 10% PEG-400 and 86% PBS-2%Tween. In the second experiment, treatment was either started at the same day of the injection of the tumor cells or after the tumors reached an average size of 200 mm3. Mice were treated every day with 0.5 mg/kg (intervention) or 1 mg/kg (therapeutic) AP20187 for 5 consecutive days. Tumor size was measured twice a week by caliper.
Immunohistochemistry and antibodies
Tumors were fixed in paraformaldehyde overnight and embedded in paraffin. Slides were cut, deparaffinized and rehydrated. Endogenous peroxidase was blocked in methanol with 0.3% H202 for 20 min. Antigen retrieval was performed by boiling the slides in antigen unmasking buffer (H-3300, Vector Brunschwig) for 10 min. Biotin-blocking was performed with the avidin/biotin blocking kit (00-4303, Zymed). Slides were blocked with 10% FCS in PBS, and then incubated overnight at 4°C with rabbit-anti-Ki67 (SP6, Neomarkers), rabbit-anti-FKBP12 (PA1-026A, Affinity Bioreagent) or mouse-anti-cytodeath (M30, Peviva). After washing, the slides were incubated for 1 h at RT with biotin-anti-mouse IgG (62-6540, Zymed) or biotin-anti-rabbit (E0432, Dako). After washing, the slides were incubated with AB Complex/HRP (K0355, Dako) and subsequently stained with DAB (K3468, Dako). Counterstain was performed with hematoxyline. Sides were dehydrated and mounted with perpex.
Apoptosis induction by dimerization of iCasp9 is independent of Bax/Bak and XIAP
Next, we set out to test whether the iCasp9 construct would induce apoptosis in the mitochondrial pathway-deficient DKO cells. To this end, we transduced WT HCT116 and the DKO cells with a vector encoding iCasp9-IRES-GFP. Treatment with 10 nM of AP20187 dimerizer resulted in a time-dependent reduction of GFP+ cells and a concomitant increase in PI+ cells after 24 h, showing that cell death is induced by dimerization (Fig. 1d, e). Only the iCasp9-IRES-GFP expressing cells die upon addition of dimerizer, while control transduced (PMX-YFP) showed no response to treatment, indicating that the cytotoxic effect is dependent on the presence of iCasp9. To directly show that the cell death is a result of apoptosis, we determined the effect of dimerizer on caspase-3 activation and DNA fragmentation. This revealed that the addition of dimerizer results in an extremely rapid onset of apoptosis. Both caspase-3 activation and DNA fragmentation were detected already after 1 h of dimerizer treatment, and PARP was even fully processed at this time point (Fig. 1f, g). Importantly, at the later time points tumor cells were completely disintegrated and we even failed to isolate sufficient amounts of protein from these dead cells as evidenced by the lack of tubulin in the samples. As expected, the induction of apoptosis is dependent on the presence of iCasp9 and not observed in HCT116 cells transduced with a control vector.
Interestingly, when DKO HCT116 cells, transduced with iCasp9, were treated with dimerizer, they responded in a similar way as the WT HCT116 cells. Also, these DKO cells displayed a quick apoptotic response to the dimerizer, while they resist 5-FU. The dimerizer induced quick DNA fragmentation, PARP and caspase-3 cleavage (Fig. 1f, g, i). In addition, the increase in PI+ cells (Fig. 1e) and decrease in GFP+ cells (Fig. 1d) was found after 24 h, indicating that dimerization of iCasp9 can induce a robust and efficient cell death, even when Bax and Bak are not present.
Taken together, the current data indicate that dimerizer-induced cell death is dependent on the presence of the iCasp9 construct, but the effectiveness does not depend on upstream signalling molecules in the apoptosis pathway like Bax and Bak.
Dimerization of iCasp9 in CSCs induces apoptosis in vitro
As these spheroid cultures do not only contain CSCs, but also more differentiated cells, as shown previously by our group , we decided to compare the effect of dimerization of iCasp9 to treatment with 5-FU in a more specific test that allows to discriminate CSCs from their differentiated progeny. This assay allows us to specifically analyse apoptosis induction within the CSC population and compare it directly to the more differentiated tumor progeny. To this end, we stained spheroid cultures for the CSC marker CD133 [1–3] and analyzed the activity of caspase-3 in CD133high (i.e. CSCs) versus CD133low cells (i.e. more differentiated tumor cells). In addition, as a supplement measurement for apoptosis we studied the expression of the early apoptosis marker Annexin-V. Treatment of CSCs for 48 h with 500 μg/ml 5-FU induced apoptosis in the more differentiated cells, whereas the CD133high CSCs were resistant (Fig. 2e, f). In contrast, treatment for 1 h with dimerizer induced apoptosis in both the CD133high and the CD133low population (Fig. 2e, f), indicating that CSCs which are normally resistant to conventional therapy can be targeted by dimerization of iCasp9.
To functionally prove that CSCs are killed by dimerization of iCasp9, we analysed the clonogenic capacity of CSCs after dimerization treatment by performing a limiting dilution assay (LDA). This assay determines the clonogenic growth of single cells derived from the spheroid cultures and is a measure for the viability of the CSCs. Spheroid cells were either pre-treated for 1 h with dimerizer or left untreated and subsequently deposited by FACS in a limiting dilution fashion. After 2 weeks, outgrowth of spheroids was scored. Untreated CSCs had a clonogenic capacity of approximately 1 in every 7 cells. However, pre-treatment of CSC with dimerizer, resulted in a dramatic decrease in clonogenicity to only 1 in every 400 cells (clone #1) or even a complete absence of spheroids after two weeks (clone #2) (Fig. 2g, h). Of note, the spheroids that did grow out after dimerization treatment were all GFP−, suggesting that they had lost the construct and thereby were rendered resistant to the induction of apoptosis. Altogether, these data show that CSCs, marked by CD133, display resistance to 5-FU treatment in vitro, while dimerization of iCasp9 also induces apoptosis in the CSC fraction and thereby loss of clonogenicity.
Dimerization of iCasp9 induces apoptosis and growth delay in vivo
H&E staining of the treated tumors revealed that dimerization of iCasp9 induced a massive loss of cells in the tumor, which was caused by cell death, as shown by the apoptotic cytodeath (M30) staining. Staining for proliferation marker Ki67 shows that cells that do survive the treatment are still highly proliferating, explaining the rapid re-growth of the tumors (Fig. 3b). When tumor cells were analyzed by FACS 48 h after the last treatment, a two- to fourfold relative decrease in epithelial cells was found, indicating that the tumor cells with iCasp9 were indeed targeted. In addition, a significant loss of GFP-positivity was observed. This confirms our observations with the second treatment of dimerizer and suggests that the iCasp9 construct in the remaining epithelial cells is either lost or inactivated. In addition, loss of expression of CSC marker CD133 was found, indicating that the CSCs were indeed targeted (Fig. 3c, d).
The in vivo experiment showed that treating tumors carrying the iCasp9 construct with dimerizer could effectively reduce tumor size, but eventually tumors will grow out again. To determine if in vivo resistance was the cause for re-growth of the tumor, we injected CSCs-iCasp9-IRES-GFP subcutaneously in mice and subsequently treated the mice for 5 consecutive days with dimerizer either directly upon tumor injection or after the tumor reached 200 mm3 (Fig. 3e). This extended treatment of the mice after tumor formation induced a better and longer reduction in tumor size and. Moreover, although the tumors eventually did grow out, this occurred with slower kinetics as compared to the original line or the one-time treated mice. In contrast, direct treatment with dimerizer after tumor injection severely inhibited tumor growth. Only 1 in 4 mice developed a tumor after 10 weeks, which displayed remarkably slower growth rates than the untreated tumors. In addition, this tumor did not show any GFP+ cells (Fig. 3f), indicating that the iCasp9 construct was lost.
We have shown that iCasp9, after chemical dimerization, can induce apoptosis in cells that are resistant to conventional therapy. First of all, cells that lack expression of Bax and Bak show no apoptotic response to 5-FU treatment, whereas, as expected, dimerization of iCasp9 induces rapid induction of cell death independent of the presence of Bax and Bak. Secondly, CSCs, known to be resistant for conventional therapy [3, 5, 27], undergo rapid apoptosis when exposed to dimerization of the iCasp9 construct, both in vitro as well as in vivo.
Bax/Bak are not required for apoptosis induction by dimerization of iCasp9 and this is not surprising as caspase-9 acts downstream of the mitochondria. Although several feed-forward amplification loops have been described between the intrinsic and extrinsic apoptosis pathway [28–30], the induction by iCasp9 is not dependent on this. So, loss of pro-apoptotic proteins can not block the effect of dimerization of iCasp9, making a very efficient tool for inducing apoptosis in chemotherapy-resistant cells.
Also, the dimerization of iCasp9 in vivo is able to target tumor cells and reduce tumor growth. The amount and frequency of treatment with the dimerizer does influence the effect, probably because the efficacy of the delivery is determined by this. A potential problem is that the construct can be inactivated or lost by the cells when they are pressure by treatment with the dimerizer. On the other hand, multiple dimerizer treatments in mice having a growing xenograft severely affected tumor growth at the long term. Additionally, intervention treatment showed that outgrowth of the tumor was almost completely abolished by dimerizer treatment, indicating that CSCs can be efficiently targeted by this treatment in vivo.
As mentioned previously, CSCs are resistant to conventional chemotherapy like 5-FU and oxaliplatin [3, 5]. In agreement, recent findings confirm the selective resistance of CSC using the ABC transporter ABCB5 (Wilson). Here, we use this knowledge and confirm that that CSCs, marked by high CD133 expression, are resistant to 5-FU, whereas they are not to dimerization of iCasp9. This suggests that CSCs are probably not completely resistant to all drugs and this resistance can be overcome by efficient induction of cell death downstream in the apoptosis pathway. As the dimerization of iCasp9 efficiently targets CSCs, their resistance mechanism is probably more upstream in the apoptosis pathway. Potentially, CSCs have blocked the apoptosis induction at the level of the mitochondria. Interestingly, in vitro treatment of breast CSCs with compounds that target the mitochondria induces efficient killing of these cells . It would be interesting to determine whether the resistance to upstream stimulation of the apoptotic pathways and the here described sensitivity to downstream pathway activation is also observed in primary samples derived from patients with cancer. In the past we have shown that also in freshly isolated tumor cells selective resistance to chemotherapy is apparent. However, whether these cells are sensitive to casp-9 dimerization remains to be established. Alternatively, additional experiments using drugs that activate downstream molecules in the apoptosis pathway could therefore be very informative for studying resistance in CSCs.
Because CSCs do not display any resistance to dimerization of iCasp9, this construct is a potential valuable tool for studying the role of CSCs in a growing tumor. It has been suggested that CSCs drive tumor growth and metastasis, but this has not been convincingly proven in in vivo experiments. Current experiments show that selection for expression of specific markers can identify the human tumor fraction that is able to xenograft in immunodeficient mice. These experiments mainly show that CSCs can initiate tumor growth upon transfer, which could reflect enhanced adherence, survival or growth in a foreign environment, but the necessity of CSCs to maintain tumor growth is unclear. Previously, circumstantial evidence for the role of CSCs in a growing tumor has been acquired by performing in vivo experiments to target CSCs in xenografts. For instance, when CRC xenografts were treated with an antibody against delta-like 4 ligand (DLL4), a ligand for the Notch signalling pathway, the tumor growth slowed down. In addition, this antibody treatment reduced stem cell frequencies, although only by two-fold, indicating that not all CSCs were targeted . A similar approach was used in a melanoma xenograft model, in which CSCs can be identified by ABCB5 expression. Melanoma xenografts, treated with an antibody against ABCB5, which can induce antibody-dependent cell-mediated toxicity, showed a clear reduction in tumor growth . Although this provides support for the idea that CSC are required for tumor growth, it is not clear whether the cytotoxic effect of the antibody treatment is unique to the CSCs or results in bystander kill. In the current in vivo experiments using dimerization of iCasp9 we observe a highly effective induction of apoptosis. This is observed in all tumor cells, but not in the stromal compartment. This therefore proves our hypothesis that selective ablation is possible. Future experiments will therefore have to be directed to CSC-specific expression of the iCasp9 construct, which would allow a timed and selective ablation of the CSC within a tumor and would provide valuable information on the role of these cells in growing tumors as compared to their role in xenograft initiation.
In conclusion, dimerization of iCasp9 induces rapid and efficient cell death, even in cancer cells that are normally resistant to conventional therapy due to overexpression of anti-apoptotic molecules or loss of pro-apoptotic molecules. Therefore, this construct is an interesting tool to study the effect of apoptosis of CSCs in a tumor model.
Kristel Kemper was supported by a scholarship of the AMC Graduate School; Jan Paul Medema was supported by an NWO VICI grant and by a Dutch Cancer Society grant (UvA2009-4416).
Conflict of interest
The authors declare that they have no conflict of interest.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.